LU500951B1 - Composition with tyrosinase inhibiting effect and its application - Google Patents

Composition with tyrosinase inhibiting effect and its application Download PDF

Info

Publication number
LU500951B1
LU500951B1 LU500951A LU500951A LU500951B1 LU 500951 B1 LU500951 B1 LU 500951B1 LU 500951 A LU500951 A LU 500951A LU 500951 A LU500951 A LU 500951A LU 500951 B1 LU500951 B1 LU 500951B1
Authority
LU
Luxembourg
Prior art keywords
composition
glabridin
resveratrol
tyrosinase
application
Prior art date
Application number
LU500951A
Other languages
English (en)
Inventor
Yan Wang
Chunjing Song
Pengwei Zhuang
Lin Zheng
Liuqing Ye
Jing Hu
Lifeng Wang
Yuanyuan Liu
Original Assignee
Univ Tianjin Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tianjin Traditional Chinese Medicine filed Critical Univ Tianjin Traditional Chinese Medicine
Priority to LU500951A priority Critical patent/LU500951B1/en
Application granted granted Critical
Publication of LU500951B1 publication Critical patent/LU500951B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (3)

Revendications
1.Composition avec effet inhibiteur de tyrosinase et son application est caractérisée en ce qu'elle est constituée de glabridine et de resvératrol dans un rapport massique de 0,33-3.
2.La composition, selon la revendication 1, est caractérisée en ce que le rapport massique de glabridine et de resvératrol est de 1.
3.La composition, selon la revendication 1 ou la revendication 2, est caractérisée en ce qu'elle est utilisée pour la préparation de médicaments ou de produits cosmétiques pour inhiber la tyrosinase.
LU500951A 2021-12-03 2021-12-03 Composition with tyrosinase inhibiting effect and its application LU500951B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LU500951A LU500951B1 (en) 2021-12-03 2021-12-03 Composition with tyrosinase inhibiting effect and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU500951A LU500951B1 (en) 2021-12-03 2021-12-03 Composition with tyrosinase inhibiting effect and its application

Publications (1)

Publication Number Publication Date
LU500951B1 true LU500951B1 (en) 2022-06-03

Family

ID=81827363

Family Applications (1)

Application Number Title Priority Date Filing Date
LU500951A LU500951B1 (en) 2021-12-03 2021-12-03 Composition with tyrosinase inhibiting effect and its application

Country Status (1)

Country Link
LU (1) LU500951B1 (fr)

Similar Documents

Publication Publication Date Title
Kil et al. Analysis of serum zinc and copper concentrations in hair loss
Ma et al. JAK2/STAT5/Bcl‐xL signalling is essential for erythropoietin‐mediated protection against apoptosis induced in PC 12 cells by the amyloid β− peptide Aβ25–35
Zhou et al. Black rice-derived anthocyanins inhibit HER-2-positive breast cancer epithelial-mesenchymal transition-mediated metastasis in vitro by suppressing FAK signaling
Gao et al. β-Cryptoxanthin induced anti-proliferation and apoptosis by G0/G1 arrest and AMPK signal inactivation in gastric cancer
Liu et al. Rosmarinic acid inhibits cell proliferation, migration, and invasion and induces apoptosis in human glioma cells
Zhang et al. The anti-carcinogenesis properties of erianin in the modulation of oxidative stress-mediated apoptosis and immune response in liver cancer
Simu et al. Ginsenoside Rg5: Rk1 exerts an anti-obesity effect on 3T3-L1 cell line by the downregulation of PPARγ and CEBPα
Weng et al. Propolin H from Taiwanese propolis induces G1 arrest in human lung carcinoma cells
Wu et al. Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition
Xie et al. Matrine inhibits the proliferation and migration of lung cancer cells through regulation of the protein kinase B/glycogen synthase kinase‑3β signaling pathways
Wei et al. Daturataturin A, a withanolide in Datura metel L., induces HaCaT autophagy through the PI3K‐Akt‐mTOR signaling pathway
Jiang et al. TIPE2 governs macrophage polarization via negative regulation of mTORC1
Ku et al. Miyabenol A inhibits LPS-induced NO production via IKK/IκB inactivation in RAW 264.7 macrophages: possible involvement of the p38 and PI3K pathways
LU500951B1 (en) Composition with tyrosinase inhibiting effect and its application
Xiong et al. Tectoridin inhibits the progression of colon cancer through downregulating PKC/p38 MAPK pathway
Koh et al. Pterostilbene enhances thermogenesis and mitochondrial biogenesis by activating the SIRT1/PGC‐1α/SIRT3 pathway to prevent western diet‐induced obesity
Li et al. The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF-κB signaling pathway
Lu et al. Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3‑kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway
Kim et al. Kaempferol tetrasaccharides restore skin atrophy via PDK1 inhibition in human skin cells and tissues: Bench and clinical studies
Dong et al. Downregulation of ROR2 promotes dental pulp stem cell senescence by inhibiting STK4‐FOXO1/SMS1 axis in sphingomyelin biosynthesis
Yoo et al. Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells
Shih et al. Green tea (−)-epigallocatechin gallate inhibits the growth of human villous trophoblasts via the ERK, p38, AMP-activated protein kinase, and protein kinase B pathways
Wu et al. Neokestose suppresses the growth of human melanoma A2058 cells via inhibition of the nuclear factor‑κB signaling pathway
Takahashi et al. Endogenous oxidative stress, but not ER stress, induces hypoxia‐independent VEGF120 release through PI3K‐dependent pathways in 3T3‐L1 adipocytes
Bhavsar et al. Involvement of the PI3K/AKT pathway in the hypoglycemic effects of saponins from Helicteres isora

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20220603